The BBB remains a major obstacle to effective treatment of CNS disorders by limiting the entry of most therapeutics into the brain. The hCMEC/D3 is widely used as anin vitromodel to study BBB structure, permeability, and drug transport. In parallel, ...
Alzheimer's disease (AD) is the most dominant and prevalent form of dementia. The therapeutic agents for AD are not sufficient. Drug repurposing (i.e., also called drug repositioning or therapeutic switching of drugs) could contribute to adding novel...
Journal of controlled release : official journal of the Controlled Release Society
Nov 27, 2025
Glioblastoma (GBM) is an aggressive central nervous system (CNS) malignancy with a poor prognosis and limited responses to conventional therapies. RNA-based therapeutics, with their gene-targeting specificity, present a promising avenue for GBM treat...
Journal of chemical information and modeling
Nov 18, 2025
Neuroscience is the most difficult therapeutic area for pharmaceutical drug discovery. The blood-brain barrier (BBB) prevents ∼100% of large molecules and >98% of small molecules from penetrating the central nervous system (CNS). Most small molecule ...
BACKGROUND: The blood-brain barrier (B) acts as a membrane that is a major concern in treating central nervous system (CNS) disorders. The B penetrating peptides (BPPs) play a significant role in delivering therapeutic drugs to a wide range of disord...
Dendrimer-based nanocarriers are emerging as transformative platforms to overcome the challenge of crossing the blood-brain barrier (BBB) in the treatment and diagnosis of central nervous system (CNS) disorders. Their highly branched, monodisperse ar...
Journal of materials science. Materials in medicine
Oct 14, 2025
Treating neurodegenerative and traumatic brain disorders is profoundly challenging due to factors like permanent tissue loss and the restrictive nature of the Blood-Brain Barrier (BBB), which limits drug delivery to the brain. Biomaterials offer a pr...
European journal of medicinal chemistry
Sep 30, 2025
Delivering small molecules to the brain and central nervous system (CNS) is greatly hindered by the restrictive blood-brain barrier (BBB), which selectively permits essential molecules while excluding toxic molecules. This selective permeability feat...
Neurological disorders continue to be a leading global health challenge, with the blood-brain barrier (BBB) presenting considerable obstacles to effective drug delivery for central nervous system (CNS) therapies. Accurately predicting BBB permeabilit...
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small mole...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.